Pulmonary vascular and cardiac impairment in interstitial lung disease

Eur Respir Rev. 2017 Jan 17;26(143):160053. doi: 10.1183/16000617.0053-2016. Print 2017 Jan.

Abstract

Pulmonary vascular and cardiac impairment is increasingly appreciated as a major adverse factor in the natural history of interstitial lung disease. This clinically orientated review focuses on the current concepts in the pathogenesis, pathophysiology and implications of the detrimental sequence of increased pulmonary vascular resistance, pre-capillary pulmonary hypertension and right heart failure in interstitial lung disease, and provides guidance on its management.

Publication types

  • Review

MeSH terms

  • Animals
  • Heart Failure / diagnosis
  • Heart Failure / etiology*
  • Heart Failure / physiopathology
  • Heart Failure / therapy
  • Hemodynamics*
  • Humans
  • Hypertension, Pulmonary / diagnosis
  • Hypertension, Pulmonary / etiology*
  • Hypertension, Pulmonary / physiopathology
  • Hypertension, Pulmonary / therapy
  • Lung Diseases, Interstitial / complications*
  • Lung Diseases, Interstitial / diagnosis
  • Lung Diseases, Interstitial / physiopathology
  • Lung Diseases, Interstitial / therapy
  • Prognosis
  • Pulmonary Circulation*
  • Risk Factors
  • Ventricular Dysfunction, Right / diagnosis
  • Ventricular Dysfunction, Right / etiology*
  • Ventricular Dysfunction, Right / physiopathology
  • Ventricular Dysfunction, Right / therapy
  • Ventricular Function, Right*